Abstract:CD19 antigen is a major target for human B cell malignancies. Many studies have shown that the antibodies recognizing this antigen hold clinical therapeutic potential, while CD19 antibody of mouse origin requires genetic engineering to reduce the potential side effects of the antibody for their clinical use. There are many clones of CD19 antibodies available with different subclasses of immunoglobulin. IgM type antibody holds a high affinity and high complement activating capacities facilitating the targeting efficacy when it is used in targeting therapy. However, engineering the murine IgM antibody into a functional humanized antibody remains a challenge. The aim of this study was to construct a chimeric antibody composed of a CD19 specific murine IgM antibody 2E8 single-chain antibody fragment (scFv) and human IgG1 Fc region, which was named 2E8scFv-Fc or Hm2E8b. The function and the biological activities of this engineered antibody were characterized using a variety of approaches including cellular, immunological, flow cytometric, and molecular biological approaches. After switching from IgM- to IgG-like type antibody, Hm2E8b retained full antigen-binding activity to membrane CD19 antigen as its parental antibody 2E8, and the immune effector function analysis revealed that it could mediate complement-dependent cytotoxicity (CDC) to kill the target cells via IgG1 Fc domain. The yield of the engineered antibody Hm2E8b in the supernatant was 13.3 μg/mL expressed and secreted in the CHO cell system, which reached the secretory quantity of a regular mouse hybridoma cells. Our conclusion is that the IgM type of CD19 mouse antibody can be successfully engineered into an IgG1 type human-mouse chimeric antibody with similar affinity and biological activity. The yield of the Hm2E8b expression and secretion in CHO cell system was adequate to facilitate further development for therapeutic purpose.

[Construction and immunological study of recombinant hBD-2/PSMA chimeric protein eukaryotic expressive plasmid].

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

Identification of MHC Class II-restricted T-cell Epitopes in Prostate-Specific Membrane Antigen.

[Construction, Expression and Purification of a Mammalian Secretory Recombinant Fusion Protein Rpc].

Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer.

[Cloning and Expression of Extracellular Domain of Prostate Specific Membrane Antigen in Escherichia Coli and Preparation of Polyclonal Antibody].

Co-delivery of PSMA antigen epitope and mGM-CSF with a cholera toxin-like chimeric protein suppressed prostate tumor growth via activating dendritic cells and promoting CTL responses

Conduction of a Prostate Cancer Whole-Cell Vaccine Modified by Mice HSP70 and GM-CSF

Antitumor Effect of a DNA Vaccine Harboring Prostate Cancer-Specific Antigen with IL-12 as an Intramolecular Adjuvant

Construction and direct immunization of eukaryotic expression plasmid encoding human soluble B lymphocyte stimulator.

Preparation and Preliminary Utilization of Monoclonal Antibodies Specifically Against Extracellular Peptide Fragment of Prostate Specific Membrane Antigen

The Construction of PCV2 DNA Vaccine and Its Immune Response in Mouse

Expression of human prostate specific antigen in Escherichia coli and preparation of PSA polyclonal antibody

Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

Co-administration of a DNA vaccine encoding the prostate specific membrane antigen and CpG oligodeoxynucleotides suppresses tumor growth

Dendritic Cells Transduced with a PSMA-encoding Adenovirus and Cocultured with Autologous Cytokine-Induced Lymphocytes Induce a Specific and Strong Immune Response Against Prostate Cancer Cells.

Construction and expression of replication-deficient recombinant adenoviral vector carrying prostate specific membrane antigen gene

Strong Humoral Response Elicited by A Dna Vaccine Targeting Gastrin-Releasing Peptide with Optimized Adjuvants Inhibits Murine Prostate Carcinoma Growth in Vivo

Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy

Antitumor Immunity by a Dendritic Cell Vaccine Encoding Secondary Lymphoid Chemokine and Tumor Lysate on Murine Prostate Cancer

Improved Efficacy of DNA Vaccination Against Prostate Carcinoma by Boosting with Recombinant Protein Vaccine and by Introduction of a Novel Adjuvant Epitope